Birinci basamakta reçeteleme trendi ve sık karşılaşılan tanılara ait reçetelerin incelenmesi: Türkiye verisi

Amaç: Bu çalışmada Türkiye’de birinci basamakta düzenlenen reçetelerin ayrıntılarının incelenmesi ve bunların yıllara göre değişiminin değerlendirilmesi amaçlandı.Gereç ve Yöntem: Türkiye’de 2013-2016 tarihleri arasında birinci basamak hekimleri tarafından yazılan ve Reçete Bilgi Sistemi’nde kayıtlı tüm elektronik reçetelerdeki ilaçların ayrıntıları incelendi. Hastaların cinsiyetleri ve yaş grupları özelinde reçete başına düşen ortalama ilaç sayıları (RBDİS) belirlendi. İncelenen yıllarda en sık karşılaşılan ilk yirmi ilacın yer aldığı reçetelerin yüzdeleri belirlendi. Dört yıllık süreçte tek tanılı reçeteler içerisinde en sık karşılaşılan on tanının yer aldığı reçetelerin yüzdesi ve RBDİS incelendi. Bulgular: Dört yılın toplamında 518.335.821 adet reçetede 1.457.034.275 kalem ilaç reçetelendiği ve RBDİS’nin 2,81 olduğu tespit edildi. Tüm yıllarda reçetelerde en fazla yer alan ilaçlar “diğer soğuk algınlığı preparatları” (%19,2-%19,7) ve “amoksisilin+beta-laktamaz inhibitörü” (%9,9-%10,5) idi. Dört yılın toplamında tek tanılı reçetelerde hipertansiyon (%6,9, RBDİS: 2,00) ve “akut üst solunum yolu enfeksiyonu, tanımlanmamış” (ÜSYE), (%6,5, RBDİS: 2,61) tanıları ilk sıralardaydı.Sonuç: Birinci basamaktaki reçetelerin daha çok kadınlara ve yaşlılara yazıldığı ve ÜSYE ile hipertansiyon endikasyon alanlarında yoğunlaştığı anlaşılmaktadır. Soğuk algınlığı preparatları, NSAİİ’ler, PPİ’ler, analjezikler ve geniş spektrumlu antibiyotiklerin fazla reçeteleniyor olması birinci basamakta rasyonel reçeteleme davranışı ile ilgili önemli sorunların varlığına işaret etmektedir. 

Investigation of prescribing trends and prescriptions for common diagnoses in primary care: Nationwide data of Turkey

IPurpose: This study aimed to examine the details of prescriptions issued in primary care and the changes over the years in Turkey.Materials and Methods: We analyzed all electronic prescriptions registered to Prescription Information System by primary care physicians in Turkey between 2013 and 2016. The mean number of drugs per prescription (nDPP) was determined by patients’ sex and age groups. The percentages of the prescriptions containing the top twenty most frequently encountered drugs were determined for each year of the study. In the four-year period, the percentage of prescriptions with the ten most common diagnoses among prescriptions with single diagnosis and nDPP were examined.Results: A total of 1.457.034.275 drugs were prescribed in 518.335.821 prescriptions and nDPP was 2.81 for the four-year period. The most commonly used drugs in all prescriptions were “other cold preparations” (19.2-19.7%) and “amoxicillin+beta-lactamase inhibitor” (9.9-10.5%). The diagnosis of hypertension (6.9%, nDPP: 2.00) and “acute upper respiratory tract infection, unspecified” (URTI), (6.5%, nDPP: 2.61) were in the top ranks in single-diagnosis prescriptions during four-year period.Conclusion: Primary care prescriptions appear to be mostly generated for women and elderly populations, with a tendency for URTI and hypertension indications. Overprescriptions of cold preparations, NSAIDs, PPIs, analgesics, and broad-spectrum antibiotics imply existence of important problems in the primary care regarding rational prescribing behavior. 

___

  • 1. Akıcı A, Uzuner A. Birinci Basamak Sağlık Kurumlarında Çalışan Hekimlere Yönelik Akılcı Ilaç Kullanımı. Ankara, T.C. Sosyal Güvenlik Kurumu Başkanlığı, 2013.
  • 2. World Health Organization. Using Indicators to Measure Country Pharmaceutical Situations: Fact Book on WHO Level I and Level II Monitoring Indicators. Geneva, Switzerland. 2006.
  • 3. Doğukan M, Yer M, Kitiz B, Gülkan S. Akılcı ilaç kullanımını yaygınlaştırma faaliyetlerine Sosyal Güvenlik Kurumunun katkıları. Türkiye Klin J Pharmacol-Special Top. 2015;3:27-33.
  • 4. Türkiye İstatistik Kurumu. Yıllara, yaş grubu ve cinsiyete göre nüfus, 1935-2018. http://www.tuik.gov.tr/PreIstatistikTablo.do?istab_i d=1588 (accessed Apr 2020).
  • 5. Wettermark B, Vlahović‐Palčevski V, Lee D, Bergman U. Studies of Drug Utilization. In Textbook of Pharmacoepidemiology (Eds Strom BL, Kimmel SE, Hennessy S.) Wiley. 2019:373-410.
  • 6. Holloway KA, Ivanovska V, Wagner AK, VialleValentin C, Ross-Degnan D. Have we improved use of medicines in developing and transitional countries and do we know how to? Two decades of evidence. Trop Med Int Heal. 2013;18:656-64.
  • 7. Mollahaliloglu S, Alkan A, Donertas B, Ozgulcu S, Akici A. Prescribing practices of physicians at different health care institutions. Eurasian J Med. 2013;45:92-8.
  • 8. Thompson AE, Anisimowicz Y, Miedema B, Hogg W, Wodchis WP, Aubrey-Bassler K. The influence of gender and other patient characteristics on health care-seeking behaviour: a QUALICOPC study. BMC Fam Pract. 2016;17:38.
  • 9. Hobbs FDR, Bankhead C, Mukhtar T, Stevens S, Perera-Salazar R, Holt T et al. Clinical workload in UK primary care: a retrospective analysis of 100 million consultations in England, 2007–14. Lancet. 2016;387:2323-30.
  • 10. Wändell P, Carlsson AC, Wettermark B, Lord G, Cars T, Ljunggren G. Most common diseases diagnosed in primary care in Stockholm, Sweden, in 2011. Fam Pract. 2013;30:506-13.
  • 11. Sturkenboom MCJM, Verhamme KMC, Nicolosi A, Murray ML, Neubert A, Caudri D et al. Drug use in children: cohort study in three European countries. BMJ. 2008;337:a2245.
  • 12. Thrane N, Sørensen HT. A one-year populationbased study of drug prescriptions for Danish children. Acta Paediatr Int J Paediatr. 1999;88:1131-6.
  • 13. Al Balushi K, Al-Sawafi F, Al-Ghafri F, Al-Zakwani I. Drug utilization pattern in an Omani pediatric population. J Basic Clin Pharm. 2013;4:68-72.
  • 14. Moriarty F, Hardy C, Bennett K, Smith SM, Fahey T. Trends and interaction of polypharmacy and potentially inappropriate prescribing in primary care over 15 years in Ireland: A repeated cross-sectional study. BMJ Open. 2015;5:e008656..
  • 15. Payne RA, Avery AJ, Duerden M, Saunders CL, Simpson CR, Abel GA. Prevalence of polypharmacy in a Scottish primary care population. Eur J Clin Pharmacol. 2014;70:575-81.
  • 16. Akıcı A. Akılcı ilaç kullanımı ilkeleri doğrultusunda yaşlılarda reçete yazma ve Türkiye’de yaşlılarda ilaç kullanımının boyutları. Turk Geriatri Dergisi, Özel Sayı. 2006:19-27.
  • 17. Mollahaliloğlu S, Alkan A, Özgülcü Ş, Öncül HG, Güney Z. Birinci Basamakta Akılcı Reçete Yazımı. Ankara, Türkiye Cumhuriyeti Sağlık Bakanlığı, Refik Saydam Hıfzıssıhha Merkezi Başkanlığı Hıfzıssıhha Mektebi Müdürlüğü, 2011.
  • 18. Başara BB, Çağlar İS, Aygün A, Özdemir TA, Kulali B, Uzun SB et al. Sağlık İstatistikleri Yıllığı 2017. Ankara, Türkiye Cumhuriyeti Sağlık Bakanlığı. 2018.
  • 19. Haas JS, Phillips KA, Gerstenberger EP, Seeer AC. Potential savings from substituting generic drugs for brand-name drugs: medical expenditure panel survey, 1997-2000. Ann Intern Med. 2005;142:1997-2000.
  • 20. Gürsöz H, Vural İM. Türkiye İlaç Pazarı Gözlem Raporu-4: Satış Hacmi ve Değeri Açısından 2015 ve 2016 Yılı Pazar Durumu. Ankara, T.C. Sağlık Bakanlığı Türkiye İlaç ve Tıbbi Cihaz Kurumu, 2018.
  • 21. T.C. Sosyal Güvenlik Kurumu. Sağlık Uygulama Tebliği (17.01.2020 Değişiklik Tebliği İşlenmiş Güncel 2013 SUT); 2020. Ankara, Sağlık Güvenlik Kurumu, 2020.
  • 22. T.C. Sağlık Bakanlığı. 2014 yılında değer bazında en yüksek satış tutarına sahi̇p ilk 100 ilacın değerlendi̇ri̇lmesi̇ ve 2012-2013 yılları ile karşılaştırılma. Ankara, T.C. Sağlık Bakanlığı 2016.
  • 23. McGettigan P, Henry D. Use of non-steroidal antiinflammatory drugs that elevate cardiovascular risk: an examination of sales and essential medicines lists in low-, middle-, and high-income countries. PLoS Med. 2013;10:e1001388.
  • 24. Moore N, Pollack C, Butkerait P. Adverse drug reactions and drug – drug interactions with over-thecounter NSAIDs. Ther Clin Risk Manag. 2015;11:1061-75.
  • 25. T.C. Sağlık Bakanlığı Türkiye İlaç ve Tıbbi Cihaz Kurumu. Diklofenak İçeren Ürünler. Sayı:46977249- 510.01.04. Ankara, Sağlık Bakanlığı, 2020.
  • 26. European Medicines Agency. New safety advice for diclofenac–CMDh endorses PRAC recommendation. EMA/380947/2013. https://www.ema.europa.eu/en/news/new-safetyadvice-diclofenac-cmdh-endorses-pracrecommendation (accessed Apr 2020).
  • 27. Kristensen KB, Karlstad Ø, Martikainen JE, Pottegård A, Wastesson JW, Zoega H et al. Nonaspirin nonsteroidal antiinflammatory drug use in the Nordic countries from a cardiovascular risk perspective, 2000–2016: a drug utilization study. Pharmacotherapy. 2019;39:150-160.
  • 28. European Medicines Agency. Assessment report for non-steroidal anti-inflammatory drugs (NSAIDs) and cardiovascular risk. EMA/696137/2012. https://www.ema.europa.eu/en/documents/referral /assessment-report-article-53-procedure-nonsteroidal-anti-inflammatory-drugs-nsaidscardiovascular_en.pdf (accessed Apr 2020).
  • 29. Hider-Mlynarz K, Cavalié P, Maison P. Trends in analgesic consumption in France over the last 10 years and comparison of patterns across Europe. Br J Clin Pharmacol. 2018;84:1324-34.
  • 30. Machado GC, Maher CG, Ferreira PH, Pinheiro MB, Lin CW, Day RO et al. Efficacy and safety of paracetamol for spinal pain and osteoarthritis: systematic review and meta-analysis of randomised placebo controlled trials. BMJ. 2015;350: h1225.
  • 31. Mash B, Fairall L, Adejayan O, Ikpefan O, Kumari J, Mathee S et al. A morbidity survey of South African primary care. PLoS One. 2012;7:e32358.
  • 32. Maç ÇE, Öztürk GZ. The comparison of patient records admitted to the family medicine polyclinics of an education and research hospital and an educational family medicine center. Ankara Med J. 2018;18:14-21.
  • 33. Gloth FM. Pain management in older adults: prevention and treatment. J Am Geriatr Soc. 2001;49:188-199.
  • 34. Witenko C, Moorman-Li R, Motycka C, Duane K, Hincapie-Castillo J, Leonard P et al. Considerations for the appropriate use of skeletal muscle relaxants for the management of acute low back pain. P T. 2014;39:427-435.
  • 35. Cohen SP, Mullings R, Abdi S. The pharmacologic treatment of muscle pain. Anesthesiology. 2004;101:495-526.
  • 36. Kamath A. Thiocolchicoside: a review. DHR Int J Med Sci. 2013;4:39-45.
  • 37. European Medicines Agency. European Medicines Agency recommends restricting use of thiocolchicoside by mouth or injection. 22 Nov 2013. https://www.ema.europa.eu/en/news/europeanmedicines-agency-recommends-restricting-usethiocolchicoside-mouth-injection (accessed Apr 2020).
  • 38. T.C. Sağlık Bakanlığı Türkiye İlaç ve Tıbbi Cihaz Kurumu. Ek izlemeye tabi ilaçlar listesi. https://www.titck.gov.tr/dinamikmodul/57?page=1 (accessed Jan 2020).
  • 39. Savarino V, Dulbecco P, de Bortoli N, Ottonello A, Savarino E. The appropriate use of proton pump inhibitors (PPIs): need for a reappraisal. Eur J Intern Med. 2017;37:19-24.
  • 40. Moriarty F, Bennett K, Cahir C, Fahey T. Characterizing potentially inappropriate prescribing of proton pump inhibitors in older people in primary care in Ireland from 1997 to 2012. J Am Geriatr Soc. 2016;64:e291-6.
  • 41. Eid SM, Boueiz A, Paranji S, Mativo C, Regina Landis BA, Abougergi MS. Patterns and predictors of proton pump inhibitor overuse among academic and nonacademic hospitalists. Intern Med. 2010;49:2561- 2568.
  • 42. Naunton M, Peterson GM, Deeks LS, Young H, Kosari S. We have had a gutful: the need for deprescribing proton pump inhibitors. J Clin Pharm Ther. 2018;43:65-72.
  • 43. Skjødt MK, Ostadahmadli Y, Abrahamsen B. Long term time trends in use of medications associated with risk of developing osteoporosis: nationwide data for Denmark from 1999 to 2016. Bone. 2019;120:94-100.
  • 44. Ahrens D, Behrens G, Himmel W, Kochen MM, Chenot JF. Appropriateness of proton pump inhibitor recommendations at hospital discharge and continuation in primary care. Int J Clin Pract. 2012;66:767-773.
  • 45. Mangin D, Lawson J, Cuppage J, Shaw E, Ivanyi K, Davis A et al. Legacy drug-prescribing patterns in primary care. Ann Fam Med. 2018;16:515-520.
  • 46. Bor S, Saritas Yuksel E. How is the gastroesophageal reflux disease prevalence, incidence, and frequency of complications (stricture/esophagitis/Barrett’s esophagus/carcinoma) in Turkey compared to other geographical regions globally? Turkish J Gastroenterol. 2017;28:4-9.
  • 47. Rui P, Okeyode T. National ambulatory medical care survey: 2016 national summary tables. Centers Dis Control Prev. https://www.cdc.gov/nchs/data/ahcd/namcs_sum mary/2016_namcs_web_tables.pdf (accessed Apr 2020).
  • 48. Antithrombotic Trialists’ (ATT) Collaboration, Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, Peto R et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009;373:1849– 60.
  • 49. Fowkes FGR, Price JF, Stewart MCW, Butcher I, Leng GC, Pell ACH et al. Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial. JAMA. 2010;303:841-8.
  • 50. Raber I, McCarthy CP, Vaduganathan M, Bhatt DL, Wood DA, Cleland JGF et al. The rise and fall of aspirin in the primary prevention of cardiovascular disease. Lancet. 2019;393:2155-2167.
  • 51. Protty MB, Wilkins SJ, Hoskins HC, Dawood BB, Hayes J. Prescribing patterns of oral antiplatelets in Wales: evolving trends from 2005 to 2016. Future Cardiol. 2018;14:277-282.
  • 52. Stuntz M, Bernstein B. Recent trends in the prevalence of low-dose aspirin use for primary and secondary prevention of cardiovascular disease in the United States, 2012–2015. Prev Med Reports. 2017;5:183-186.
  • 53. Gaziano JM, Brotons C, Coppolecchia R, Cricelli C, Darius H, Gorelick PB et al. Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial. Lancet. 2018;392:1036-46.
  • 54. McNeil JJ, Nelson MR, Woods RL, Lockery JE, Wolfe R, Reid CM et al. Effect of aspirin on all-cause mortality in the healthy elderly. N Engl J Med. 2018;379:1519-28.
  • 55. Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL et al. 2016 European guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2016;37:2315-81.
  • 56. Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. Circulation. 2019;140:e596–e646.
  • 57. Isbister GK, Prior F, Kilham HA. Restricting cough and cold medicines in children. J Paediatr Child Health. 2012;48:91-98.
  • 58. European Medicines Agency. Codeine not to be used in children below 12 years for cough and cold. EMA/249413/2015. http://www.ema.europa.eu/docs/en_GB/document _library/Referrals_document/Codeine_cough_or_co ld_in_children/Position_provided_by_CMDh/WC5 00186159.pdf (accessed Apr 2020).
  • 59. van Driel ML, Scheire S, Deckx L, Gevaert P, De Sutter A. What treatments are effective for common cold in adults and children? BMJ. 2018;363:k3786.
  • 60. Mollahaliloǧlu S, Alkan A, Dönertaş B, Özgülcü Ş, Dilmen U, Akıcı A. Tek enfeksiyon tanılı reçetelere hekimlerin yazdığı antibiyotiklerin değerlendirilmesi. Marmara Pharm J. 2012;16:206-12.
  • 61. Isler B, Keske S, Aksoy M, Azap ÖK, Yilmaz M, Yavuz SŞ et al. Antibiotic overconsumption and resistance in Turkey. Clin Microbiol Infect. 2019;25:651-3.
  • 62. Shapiro DJ, Hicks LA, Pavia AT, Hersh AL. Antibiotic prescribing for adults in ambulatory care in the USA, 2007-09. J Antimicrob Chemother. 2014;69:234-40.
  • 63. Finley CR, Chan DS, Garrison S, Korownyk C, Kolber MR, Campbell S et al. What are the most common conditions in primary care? Systematic review. Can Fam Physician. 2018;64:832-40.
  • 64. World Health Organization. The top 10 causes of death - Global health estimates 2016: deaths by cause, age, sex, by country and by region, 2000-2016. Geneva; 2018. https://www.who.int/healthinfo/global_burden_dis ease/GHE2016_Deaths_Global_2000_2016.xls (accessed Apr 2020).
  • 65. James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J et al. 2014 Evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311:507-20.
  • 66. Wiliams B, Mancia G, Spiering W, Rosei EA, Azizi M, Burnier M et al. 2018 ESC/ESH guidelines for the management of arterial hypertension. The task force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH). J Hypertens. 2018;36:1953-2041.
  • 67. Sarganas G, Buttery AK, Zhuang W, Wolf IK, Grams D, Rosairo AS et al. Prevalence, trends, patterns and associations of analgesic use in Germany. BMC Pharmacol Toxicol. 2015;16:28.
  • 68. Sundbøll J, Adelborg K, Mansfield KE, Tomlinson LA, Schmidt M. Seventeen-year nationwide trends in antihypertensive drug use in Denmark. Am J Cardiol. 2017;120:2193-2200.
Cukurova Medical Journal-Cover
  • ISSN: 2602-3032
  • Yayın Aralığı: Yılda 4 Sayı
  • Başlangıç: 1976
  • Yayıncı: Çukurova Üniversitesi Tıp Fakültesi
Sayıdaki Diğer Makaleler

Şanlıurfa’nın Halfeti ilçesindeki akut gastroenteritli çocuklarda rotavirüs ve adenovirüs sıklığı

Adnan BARUTÇU, Saliha BARUTÇU

Farklı etyolojilere bağlı maküler ödem tedavisinde deksametazon implantın etkinliği

Emrah ÖZTÜRK, Burak ESENER, Abuzer GÜNDÜZ

Simülasyonun hemşirelik öğrencilerinde hasta haklarını korumaya yönelik etkileri: Kalitatif bir çalışma

Zehra GÖÇMEN BAYKARA, Evrim EYİKARA, Nurcan ÇALIŞKAN

Bir eğitim hastanesinde farmakovijilans merkezine yönlendirilen yatan hastalardaki advers ilaç reaksiyonlarının analizi

Zakir KHAN, Emine ÖZ EKEMEN, Olcay KIROĞLU, Yusuf KARATAŞ

Laparoskopik endometrioma kistektomi cerrahilerinde elektrokoagülasyon veya sütür tekniği ile sağlanan hemostazın rekürrens ve gebelik sağlama oranına etkisi

Şükrü YILDIZ, Cihan KAYA, İsmail ALAY, Murat EKİN, Levent YAŞAR

Sağlıklı Türk popülasyonunda sella turcica tiplerinin belirlenmesi

Sema ÖZANDAÇ POLAT, Ayşe Gül KABAKCI, Fatma Yasemin ÖKSÜZLER, Mahmut OKSÜZLER, Ahmet Hilmi YÜCEL

Perkütan kapatmaya şiddetli pulmoner hipertansiyonu olan patent duktus arteriozusda şans verilebilir

Ömer TEPE, Çağlar ÖZMEN, Ali DENİZ, Nazan ÖZBARLAS, Mehmet TOPÇUOĞLU

Koksartrozda uygulanan çimentosuz total kalça protezinin klinik sonuçları

Melih BAĞIR, Ahmet YILMAZ

Geriatrik bireylerde bel ağrısı riski

Nesrin YAĞCI, Uğur CAVLAK, Emre BASKAN, Mücahit ÖZTOP

Sjögren sendromu ve şiddetli cilt tutulumu mevcut olan katastrofik antifosfolipid sendromu

Ebru KARAGÜN, Birgül ÖNEÇ, Türkay AKBAŞ, Mehmet GAMSIZKAN